Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Peripheral T-Cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03212937
What this trial is testing

Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
National Cancer Centre, Singapore 11
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Very early researchUnknownNCT06224049
What this trial is testing

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Who this might be right for
T-cell Lymphoma
BGI, China 6
Testing effectiveness (Phase 2)Study completedNCT03820596
What this trial is testing

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Who this might be right for
Safety and Efficacy
Huiqiang Huang 40
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
Large-scale testing (Phase 3)Study completedNCT00877656
What this trial is testing

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Who this might be right for
T Cell Lymphoma
Emergent BioSolutions 21
Testing effectiveness (Phase 2)Ended earlyNCT04425070
What this trial is testing

Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Who this might be right for
Peripheral T-cell LymphomaNK/T-cell Lymphoma
Antengene Corporation 56
Testing effectiveness (Phase 2)Looking for participantsNCT04512534
What this trial is testing

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Fudan University 51
Testing effectiveness (Phase 2)UnknownNCT04745234
What this trial is testing

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Who this might be right for
Cutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma Refractory
Kyowa Kirin, Inc. 34
Testing effectiveness (Phase 2)Ended earlyNCT01036399
What this trial is testing

Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients

Who this might be right for
Peripheral T-cell Lymphoma
University of Bologna 9
Testing effectiveness (Phase 2)Study completedNCT03372057
What this trial is testing

Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-cell Lymphoma
SecuraBio 156
Post-approval studies (Phase 4)UnknownNCT04038411
What this trial is testing

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma
Mingzhi Zhang 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04414163
What this trial is testing

IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Who this might be right for
Extranodal NK/T-cell Lymphoma, Nasal TypeExtranodal NK/T-cell Lymphoma
ImmuneOncia Therapeutics Inc. 23
Early research (Phase 1)WithdrawnNCT00458744
What this trial is testing

Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment

Who this might be right for
Brain and Central Nervous System TumorsLeukemiaLymphoma+1 more
Children's Oncology Group
Testing effectiveness (Phase 2)UnknownNCT04994210
What this trial is testing

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Who this might be right for
Safety and Efficacy
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Study completedNCT00601718
What this trial is testing

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+34 more
University of Washington 29
Early research (Phase 1)Study completedNCT04447027
What this trial is testing

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Who this might be right for
Cutaneous T-Cell LymphomaMature T-cell MalignanciesPeripheral T-Cell Lymphoma+1 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)WithdrawnNCT00837174
What this trial is testing

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Who this might be right for
Non-Hodgkin Lymphoma
The Methodist Hospital Research Institute
Very early researchUnknownNCT04028440
What this trial is testing

ΓδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Non-Hodgkin's LymphomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaChronic Lymphoblastic Leukemia+1 more
Institute of Hematology & Blood Diseases Hospital, China 6
Next Page